Turning Point Therapeutics to Participate in 42nd Annual Cowen Healthcare Conference - Update
Turning Point Therapeutics (NASDAQ: TPTX) has announced a change in the schedule for a fireside chat with President and CEO Athena Countouriotis, M.D. The session will now occur on Tuesday, March 8, from 2:50 to 3:20 p.m. ET. Interested parties can access the chat via webcast on the company’s Investors page. The company focuses on precision oncology, developing therapies for cancer with its lead candidate, repotrectinib, addressing ROS1 and TRK oncogenic drivers. It also has a robust pipeline targeting various cancer-related genetic alterations.
- None.
- None.
SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that due to a conference schedule change, the fireside chat with President and CEO Athena Countouriotis, M.D., will now take place on Tuesday, March 8 from 2:50 to 3:20 p.m. ET.
The session will be accessible via webcast through the Investors page of www.tptherapeutics.com.
About Turning Point Therapeutics Inc.
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib, which is being studied in a registrational Phase 2 study in adults and a Phase 1/2 study in pediatric patients, has shown antitumor activity and durable responses among kinase inhibitor treatment-naïve and pre-treated patients. The company’s pipeline of drug candidates also includes elzovantinib, targeting MET, CSF1R and SRC, which is being studied in a Phase 1 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, targeting RET, which is being studied in a Phase 1/2 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in RET; and TPX-0131, a next-generation ALK inhibitor, which is being studied in a Phase 1/2 trial of previously treated patients with ALK-positive advanced or metastatic non-small cell lung cancer. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment. For more information, visit www.tptherapeutics.com.
Contact:
Adam Levy
ir@tptherapeutics.com
858-867-6366
FAQ
What is the date and time for the TPTX fireside chat?
How can I access the TPTX fireside chat?
What is the focus of Turning Point Therapeutics?
What is the lead drug candidate of TPTX?
What trials are ongoing for TPTX's drug candidates?
